Inify Laboratories expands diagnostics, UK lab on track after strong Q3 sales

Inify Laboratories reported a strong Q3 2025, marked by the successful launch of gastroenterology diagnostic services in Sweden. Initial patient samples were diagnosed in September, targeting a market with substantial demand. The company experienced 76% sales growth in Q3 compared to the previous year, and 78% for the January-September period, with Inify Laboratories Nordics maintaining a positive cash flow. Cash reserves stood at SEK 112.2 million by the quarter's end.

Construction of the UK laboratory in Milton Park, near Oxford, is progressing as planned, with clinical operations targeted to commence in early 2026. Dialogues with NHS customers for prostate cancer diagnostics are well underway, and gastroenterology services are slated for a phased introduction in the UK following their Swedish launch. The company's vision is to leverage standardized data to advance cancer research and diagnostics.

Inify Laboratories' Q3 2025 interim report detailed net sales of TSEK 4,991 and an EBITDA of TSEK -13,827. The company’s equity amounted to TSEK 127,629, with a capital adequacy ratio of 83.1%. The report highlighted ongoing investments in the UK laboratory and continued development of its diagnostic systems.